PFE Jan 2025 42.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:42PM EDT. Market open.
Loading interactive chart…
- Zacks
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
- Zacks
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
- Business Wire
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
NEW YORK, June 14, 2024--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM). The study demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.
© 2024 Yahoo. All rights reserved.